Anbio Biotechnology Shareholder Meetings Approve Major Capital Restructuring and Governance Changes

Anbio Biotechnology filed a Form 6-K reporting on shareholder meetings held on May 15, 2026, where shareholders approved significant corporate restructuring. The company held both a Class A Meeting and an Extraordinary General Meeting (EGM) that approved multiple proposals including: a share capital reduction reducing par value from $0.0001 to $0.000000001 per share; a massive authorized share capital increase from $0.50 to $3,000, creating 799.6 billion Class A shares, 199.9 billion Class B shares, 1 trillion Class C shares, and 1 trillion preference shares; an increase in Class B voting rights from 50 to 500 votes per share; Class B conversion rights allowing conversion to Class A shares; share consolidation authorization allowing reverse splits up to 10,000:1; and adoption of new amended and restated memorandum and articles of association. The EGM had high participation with 99.8% of Class A shares and 100% of Class B shares represented. The changes significantly restructure the company's capital and governance framework, particularly enhancing the voting power of Class B shareholders.